Ventana Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application is submitted for the CB11 antibody for use by physicians in deciding whether metastatic breast cancer patients should receive Genentech's Herceptin drug. While Herceptin is intended to treat metastatic breast cancer patients that test positive for Her-2/neu receptor overexpression, the firm believes CB11 is better at predicting response to the therapy than polyclonal antibodies to Her-2/neu
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.